This randomized clinical trial examines whether combined sorafenib and hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin is associated with improved survival of patients with hepatocellular carcinoma and portal vein invasion compared with sorafenib alone, the current standard systemic treatment.
This nonrandomized phase 2 clinical trial evaluates the safety and feasibility of using magnetic resonance imaging criteria to select patients with “good prognosis” rectal tumors for primary surgery.
This population-based cohort study assesses 5 measures of body composition to determine which measures are associated with major adverse cardiovascular events in patients with colorectal cancer.
This multiple-cohort study quantifies the association of black race with long-term survival outcomes after controlling for known prognostic variables and access to care among men with prostate cancer.
This cohort study investigates whether the prevalence of human papillomavirus (HPV) DNA after completion of primary cancer therapy is associated with recurrence-free survival and overall survival among patients with HPV-positive head and neck squamous cell carcinoma.
This phase 2 randomized clinical trial examines whether hydroxychloroquine sulfate improves overall survival at 1 year in combination with gemcitabine hydrochloride and nab-paclitaxel among previously untreated adults with metastatic pancreatic cancer.
This phase 1 dose-escalation trial compares the safety, tolerability, and pharmacokinetics of PF-06801591, a monoclonal antibody, administered subcutaneously vs intravenously in patients with advanced or metastatic solid tumors.
This systematic review and meta-analysis describes the various adverse events associated with PD-1 and PD-L1 inhibitor drugs reported in clinical trials indexed in PubMed, Web of Science, Embase, and Scopus.
This single-arm phase 2 clinical trial evaluates the margin-negative resection rate in locally advanced pancreatic cancer after neoadjuvant FOLFIRINOX (fluorouracil, irinotecan, and oxaliplatin) and losartan therapy and individualized chemoradiotherapy.
This cohort study of 1.5 million ED visits examines rates, costs, and outcomes of emergency department visits by patients with cancer who are undergoing chemotherapy or radiotherapy.
This nonrandomized clinical trial of women with ductal carcinoma in situ examines reasons for conversion to mastectomy after magnetic resonance imaging and adherence to radiotherapy use guided by the 12-gene ductal carcinoma in situ score.
This cohort study examines the pathophysiologic processes of autoimmune tissue and tumor toxic effects in patients with non–small cell lung cancer.
This post hoc analysis of a multi-institution cohort study assesses the association between androgen receptor perturbation and poorer outcome in patients with TP53 wild-type metastatic castration-resistant prostate cancer who are receiving abiraterone or enzalutamide.
In this cohort modeling study, the acute myeloid leukemia composite model is updated using the European LeukemiaNet 2017 classification for cytogenetic and/or molecular risks.
This systematic review examines the association of immune checkpoint inhibitor therapy with immune-related adverse effects, antitumor activity, and viral load in patients with HIV infection and advanced-stage cancer.
A 30-year-old woman presented with a history of thickened, verrucous, hyperpigmented plaques distributed symmetrically over her body. She also had recent weight loss and an enlarged thyroid. What is your diagnosis?
A 70-year-old woman with pedal edema and a history of smoking presented with multiple well-defined, palpable, purpuralike lesions on the lower extremities that gradually extended to the trunk. What is your diagnosis?
This Viewpoint distinguishes the role of global oncologists and suggests that institutions should take meaningful steps to facilitate and provide incentives for global health careers.
This Viewpoint describes the potential benefits associated with reimbursing patients for participation in cancer clinical trials.
This Viewpoint discusses the possibilities and limitations of tumor mutation burden as a biomarker for overall survival in non–small cell lung cancer.
This JAMA Patient Page describes next generation sequencing, which allows physicians to test many genes of a cancer simultaneously.
This essay describes the author’s experience as a genetic counselor with a patient with terminal pancreatic cancer.
Create a personal account or sign in to: